Tough transparency rules could harm innovation, researchers warn

FDA premarket approval submissions are more often backed by patents produced by physician-owned startups than patents from nonphysician-owned startups, a Wolters Kluwer Health study finds. Researchers warn that enforcing burdensome financial disclosure rules could deter medtech firms from investing in physician-owned startups, which could hurt innovation.